Trial Profile
A Phase Ia, Double-blind, Randomized, Placebo-controlled, Ascending IV Single-dose Study to Evaluate the Safety and Pharmacokinetics of ch mAb7F9 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs IXT-m200 (Primary)
- Indications Substance-related disorders
- Focus Adverse reactions; First in man
- Sponsors InterveXion Therapeutics
- 10 Apr 2014 New trial record